Literature DB >> 24277036

Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.

Thomas J Dilworth1, Jora Sliwinski, Keenan Ryan, Monique Dodd, Renée-Claude Mercier.   

Abstract

Vancomycin with piperacillin-tazobactam is used as empirical therapy for critically ill patients. Studies of this combination against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. aureus (VISA) are limited, but β-lactams in combination with vancomycin have shown synergistic activity against MRSA and VISA. The goal of this study was to evaluate whether piperacillin-tazobactam and vancomycin were synergistic against MRSA and VISA in vitro. Bloodstream MRSA (n = 20) and VISA (n = 4) strains were selected. In vitro antimicrobial activities of piperacillin-tazobactam and oxacillin were evaluated by disk diffusion, and MICs were determined by Etest using Muller-Hinton agar with and without vancomycin at one-half the MIC. Time-kill studies evaluated 14 MRSA and all 4 VISA isolates using piperacillin-tazobactam at 300/35 mg/liter or oxacillin at 40 mg/liter alone and with vancomycin at one-half the MIC. Mean zones of inhibition for piperacillin-tazobactam and oxacillin increased with vancomycin against MRSA and VISA (P < 0.001 for all), and the MIC90 decreased with vancomycin against MRSA and VISA to values meeting susceptibility criteria for S. aureus (P < 0.001 for both antibiotics against MRSA). In MRSA time-kill studies, the mean 24-h reductions in inoculum for piperacillin-tazobactam, piperacillin-tazobactam with vancomycin, and oxacillin with vancomycin were 3.53, 3.69, and 2.62 log10 CFU/ml, respectively. The mean 24-h reductions in VISA inoculum for piperacillin-tazobactam, piperacillin-tazobactam with vancomycin, and oxacillin with vancomycin were 2.85, 2.93, and 3.45 log10 CFU/ml, respectively. Vancomycin with piperacillin-tazobactam or oxacillin demonstrated synergistic activity against MRSA and VISA. The clinical implications of these combinations against MRSA and VISA should be investigated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24277036      PMCID: PMC3910859          DOI: 10.1128/AAC.01888-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Authors:  Benjamin P Howden; Peter B Ward; Patrick G P Charles; Tony M Korman; Andrew Fuller; Philipp du Cros; Elizabeth A Grabsch; Sally A Roberts; Jenny Robson; Kerry Read; Narin Bak; James Hurley; Paul D R Johnson; Arthur J Morris; Barrie C Mayall; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

2.  Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux.

Authors:  Kyu Y Rhee; David F Gardiner; Macarthur Charles
Journal:  Clin Infect Dis       Date:  2005-06-01       Impact factor: 9.079

3.  Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

Authors:  R Monina Klevens; Jonathan R Edwards; Fred C Tenover; L Clifford McDonald; Teresa Horan; Robert Gaynes
Journal:  Clin Infect Dis       Date:  2005-12-19       Impact factor: 9.079

4.  An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  J Antimicrob Chemother       Date:  1997-04       Impact factor: 5.790

5.  Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics.

Authors:  K Sieradzki; A Tomasz
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

6.  In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

Authors:  S Rochon-Edouard; M Pestel-Caron; J F Lemeland; F Caron
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

8.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

10.  In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.

Authors:  Lorenzo Drago; Elena De Vecchi; Lucia Nicola; Maria Rita Gismondo
Journal:  BMC Infect Dis       Date:  2007-09-21       Impact factor: 3.090

View more
  13 in total

1.  Antibiotics: Synergistic MRSA combinations.

Authors:  Karen Bush
Journal:  Nat Chem Biol       Date:  2015-11       Impact factor: 15.040

Review 2.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

3.  Top Guns: The "Maverick" and "Goose" of Empiric Therapy.

Authors:  Stephen W Davies; Jimmy T Efird; Christopher A Guidry; Zachary C Dietch; Rhett N Willis; Puja M Shah; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-10-20       Impact factor: 2.150

4.  Antibiotics in Development for the Treatment of Resistant Bacterial Disease.

Authors:  Ryan Kidd; Scot Walker
Journal:  Hosp Pharm       Date:  2017-11-07

5.  Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.

Authors:  Xuting Zheng; Andrew D Berti; Sue McCrone; Melanie Roch; Adriana E Rosato; Warren E Rose; Baiyi Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

8.  Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?

Authors:  Yamuna Devi Bakthavatchalam; Ravikar Ralph; Balaji Veeraraghavan; Priyanka Babu; Elakkiya Munusamy
Journal:  Infect Dis Ther       Date:  2018-11-21

9.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279

10.  Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis.

Authors:  Sara Alosaimy; Noor L Sabagha; Abdalhamid M Lagnf; Evan J Zasowski; Taylor Morrisette; Sarah C J Jorgensen; Trang D Trinh; Ryan P Mynatt; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2020-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.